睿知中国医院研究地图
候选清单

上海复旦大学

复旦大学附属眼耳鼻喉科医院

Eye & ENT Hospital of Fudan University

在本站收录的 53 种疾病中,这家医院列在其中 7 种下,依据是它牵头的研究论文,以及它作为牵头方或研究中心登记的试验。

这里展示的是公开记录中的研究活动,不是医疗水平评级。能否为某位患者提供帮助,应由医院和主治医生判断。

这家医院的官网还没有核对。

联系这家医院

复旦大学附属眼耳鼻喉科医院的研究

选择一种疾病,查看背后的论文和试验。 每个方块显示 2021–2025 年牵头的论文数和每年的数量。

只包括本站收录的 53 种疾病。未列出某种疾病,表示在这些记录中这家医院没有达到该病的列出标准,不代表它不诊治该病。 哪些医院会被列出

  1. 鼻咽癌Nasopharyngeal carcinoma32 篇牵头论文牵头 4 项开放试验
  2. 视网膜母细胞瘤Retinoblastoma6 篇牵头论文牵头 3 项开放试验
  3. 脊索瘤Chordoma0 篇牵头论文
  4. 神经母细胞瘤Neuroblastoma5 篇牵头论文牵头 1 项开放试验
  5. 大动脉炎Takayasu arteritis0 篇牵头论文
  6. 白塞病Behçet disease0 篇牵头论文
  7. Leber 遗传性视神经病变Leber hereditary optic neuropathy1 篇牵头论文

未列出的收录疾病:食管鳞状细胞癌、肝细胞癌、胃癌、肝母细胞瘤、骨肉瘤、胃肠道间质瘤、尤文肉瘤、多发性骨髓瘤、B 细胞急性淋巴细胞白血病、再生障碍性贫血、噬血细胞性淋巴组织细胞增生症、β 地中海贫血、血友病 A、非典型溶血性尿毒症综合征、血栓性血小板减少性紫癜、范可尼贫血、视神经脊髓炎谱系疾病、IgG4相关性疾病、重症肌无力、烟雾病、肝豆状核变性、胆道闭锁、抗 NMDA 受体脑炎、肝包虫病、特发性肺纤维化、肺淋巴管平滑肌瘤病、肌萎缩侧索硬化症、脊髓性肌萎缩症、法布雷病、庞贝病、杜氏肌营养不良、Alport 综合征、IgA 肾病、戈谢病、尼曼-匹克病 C 型、成骨不全症、原发性胆汁性胆管炎、原发性硬化性胆管炎、先天性膈疝、先天性巨结肠、遗传性大疱性表皮松解症、遗传性血管性水肿、家族性腺瘤性息肉病、Majeed 综合征、NGLY1 缺乏症、ISG15 缺乏症。

癌症

鼻咽癌

Nasopharyngeal carcinoma

2021–2025 年中国大陆作者发表的 2,375 篇鼻咽癌 PubMed 英文论文中,这家医院牵头了 32 篇,占 1.4%。

牵头论文
32
2021–2025 年
牵头试验
10
任何状态,ClinicalTrials.gov
牵头的开放试验
4
正在或即将招募
作为研究中心的开放试验
3
由其他机构牵头
每年牵头的论文数
2021: 6620212022: 2220222023: 8820232024: 7720242025: 992025

上海有 10 家医院列在鼻咽癌下全国有 183 家医院列在鼻咽癌下

这家医院参与的开放试验 7

依据 ClinicalTrials.gov 在 2026年11月8日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    Becotatug Vedotin 联合 PD-1 抑制剂用于局部晚期复发性鼻咽癌Becotatug Vedotin Combined With a PD-1 Inhibitor in the Treatment of Locally Advanced Recurrent Nasopharyngeal Carcinoma.
    分期
    II期
    开始
    2026-08
    登记号
    NCT07781358

    年龄 18 岁 至 80 岁(登记的条件)

    牵头:复旦大学附属眼耳鼻喉科医院上海

  2. 正在招募
    早期复发性鼻咽癌:辅助治疗与单纯手术比较Adjuvant vs Surgery Only in Early-stage Recurrent NPC
    分期
    III期
    开始
    2024-06
    登记号
    NCT06228079

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:复旦大学附属眼耳鼻喉科医院;另有 6 家列出的医院为研究中心上海、南宁、深圳、福州

  3. 正在招募
    局部晚期复发性鼻咽癌:新辅助治疗与辅助治疗比较Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC
    分期
    III期
    开始
    2024-07
    登记号
    NCT06235203

    年龄 18 岁 至 75 岁(登记的条件)

    牵头:复旦大学附属眼耳鼻喉科医院;另有 6 家列出的医院为研究中心上海、南宁、深圳、福州

  4. 即将招募
    早期复发性鼻咽癌:手术与调强放疗(IMRT)的效果比较Early Recurrent Nasopharyngeal Cancer: the Effect of Surgery vs IMRT
    分期
    III期
    开始
    2021-03
    登记号
    NCT04215510

    年龄 18 岁 至 70 岁(登记的条件)

    牵头:复旦大学附属眼耳鼻喉科医院;另有 3 家列出的医院为研究中心上海、南昌、福州

  5. 正在招募
    QL1706(PD-1/CTLA-4 双特异性抗体)联合放化疗用于局部区域晚期鼻咽癌QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.
    分期
    III期
    开始
    2025-05
    登记号
    NCT06749899

    年龄 18 岁 至 65 岁(登记的条件)

    牵头:中山大学肿瘤防治中心;另有 17 家列出的医院为研究中心上海、东莞、中山、佛山、南京、南宁、厦门、天津、广州、成都、武汉、福州、贵阳、长沙

  6. 正在招募
    鼻咽癌个体化颈部预防性照射试验Individualized Neck Cervical Irradiation Prophylaxis Trial of NPC
    分期
    III期
    开始
    2025-09
    登记号
    NCT07303023

    年龄 18 岁 至 70 岁(登记的条件)

    牵头方不是列出的医院;另有 6 家列出的医院为研究中心上海、成都、杭州、重庆

  7. 正在招募
    喉咽清口服液防治鼻咽癌放射性口腔黏膜炎Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid
    分期
    III期
    开始
    2025-12
    登记号
    NCT07311772

    年龄 18 岁 至 75 岁(登记的条件)

    牵头方不是列出的医院;另有 16 家列出的医院为研究中心上海、北京、南宁、常州、广州、成都、昆明、杭州、梧州、汕头、珠海、福州、长沙

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。卡片标题如有中文,为 AI 生成的译文,英文原文附后。

这些数字背后的记录
研究主题复发与转移放疗技术影像与人工智能
论文中的科室耳鼻喉/头颈外科放疗科影像/核医学科眼科/神经眼科
牵头的论文32
  1. Machine learning for predicting distant metastasis in nasopharyngeal carcinoma patients.2025Frontiers in immunology免费全文
  2. EC-IC Bypass for Skull Base Necrosis and ICA Rupture Hemorrhage After Radiotherapy for Nasopharyngeal Carcinoma.2025Head & neck
  3. Mucosal Flap Reconstruction Enhances Survival in Salvage Endoscopic Nasopharyngectomy for Recurrent Nasopharyngeal Carcinoma: A Propensity-Matched Cohort Study.2025International forum of allergy & rhinology
  4. Down-regulation of PCK2 enhanced the radioresistance phenotype of nasopharyngeal carcinoma.2025International journal of radiation biology
  5. Tislelizumab as adjuvant therapy following endoscopic surgery for resectable recurrent nasopharyngeal carcinoma: a randomized clinical trial.2025Journal for immunotherapy of cancerRCT免费全文
  6. A prospective cross-sectional-comparative analysis of nutrition screening and assessment tools in chinese nasopharyngeal carcinoma inpatients undergoing radiotherapy using Global Leadership Initiative on Malnutrition criteria as the gold st2025Nutrition in clinical practice : official publication of the American Society for Parenteral and Enteral Nutrition
  7. Feasibility of modified target volumes to meet potential therapeutic needs for nasopharyngeal carcinoma.2025Radiography (London, England : 1995)
  8. A qualitative analysis of fear of cancer recurrence among Chinese nasopharyngeal cancer patients who are undergoing active treatment.2025Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer免费全文
  9. Artificial intelligence-assisted detection of nasopharyngeal carcinoma on endoscopic images: a national, multicentre, model development and validation study.2025The Lancet. Digital health
  10. Neoadjuvant chemotherapy for organ preservation in sinonasal squamous cell carcinoma.2024European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery
  11. Magnetic resonance imaging based on radiomics for differentiating T1-category nasopharyngeal carcinoma from nasopharyngeal lymphoid hyperplasia: a multicenter study.2024Japanese journal of radiology
  12. Bilateral Oculomotor Ocular Neuromyotonia-A Rare Case Due to Nasopharyngeal Carcinoma Radiotherapy.2024Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society
  13. Identifying biomarkers for nasopharyngeal carcinoma diagnosis and chemoradiotherapy response using serum endogenous small molecules profiling.2024Journal of pharmaceutical and biomedical analysis
  14. Gemcitabine, capecitabine, and tislelizumab in recurrent/metastatic nasopharyngeal carcinoma following prior anti-PD-1 therapy failure: A retrospective study.2024Oral oncology
  15. Efficacy and Safety of Immune Checkpoint Inhibitors Combined With Chemotherapy as First-line Treatment for Recurrent or Metastatic Nasopharyngeal Carcinoma: A Network Meta-analysis of Randomized Controlled Trials.2024The Annals of pharmacotherapy
  16. Anatomical studies and early results on endoscopic transoral medial pterygomandibular fold approach to salvage retropharyngeal lymphadenectomy in nasopharyngeal carcinoma.2024The Journal of laryngology and otology
  17. Preliminary evidence for endoscopic surgery combined with postoperative anti-PD-1 immunotherapy in advanced recurrent nasopharyngeal carcinoma.2023BMC cancer免费全文
  18. Changes in brain gray matter volume in nasopharyngeal carcinoma patients after radiotherapy in long-term follow-up.2023Brazilian journal of otorhinolaryngology免费全文
  19. Elderly nasopharyngeal carcinoma patients (aged ≥70 years): Survival and treatment strategies.2023Cancer medicine免费全文
  20. Pretreatment dual-energy CT for predicting early response to induction chemotherapy and survival in nasopharyngeal carcinoma.2023European radiology
  21. Innovative Fudan rT staging in endoscopic surgery for recurrent nasopharyngeal carcinoma.2023Head & neck
  22. Endoscopic surgery is superior to intensity-modulated radiotherapy in the treatment of advanced recurrent nasopharyngeal carcinoma.2023International forum of allergy & rhinology
  23. Salvage endoscopic surgery for skull base osteoradionecrosis in nasopharyngeal carcinoma patients: A prospective, observational, single-arm clinical study.2023Rhinology
  24. Transoral robotic resection of advanced recurrent nasopharyngeal carcinoma involving the internal carotid artery.2023The international journal of medical robotics + computer assisted surgery : MRCAS
  25. Circular RNAs: Functions and mechanisms in nasopharyngeal carcinoma.2022Head & neck
  26. Authors' reply - "Innovative application of internal carotid artery embolization in salvage endoscopic nasopharyngectomy for recurrent nasopharyngeal carcinoma: A case-matched comparison".2022International forum of allergy & rhinology
  27. Salvage Endoscopic Nasopharyngectomy in Recurrent Nasopharyngeal Carcinoma: Prognostic Factors and Treatment Outcomes.2021American journal of rhinology & allergy
  28. Identification of key pseudogenes in nasopharyngeal carcinoma based on RNA-Seq analysis.2021BMC cancer免费全文
  29. Circular RNA TGFBR2 acts as a ceRNA to suppress nasopharyngeal carcinoma progression by sponging miR-107.2021Cancer letters
  30. Is Immune Therapy Plus Chemotherapy More Effective Than Immune Therapy Alone for Unresectable Recurrent Nasopharyngeal Carcinoma?2021Frontiers in immunology免费全文
  31. Establishment and validation of a novel nomogram to predict overall survival in nasopharyngeal carcinoma with lymph node metastasis.2021Head & neck
  32. Nano-Coated si-SNHG14 Regulated PD-L1 Expression and Decreased Epithelial-Mesenchymal Transition in Nasopharyngeal Carcinoma Cells.2021Journal of biomedical nanotechnology
中文论文(未计入)9
  1. [Transfer learning-based endoscopic image recognition of nasopharyngeal carcinoma: investigating pre-trained large models in small sample settings].2025Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  2. [Endoscopic transoral approach nasopharyngectomy for petroclival and jugular foramen nasopharyngeal carcinoma].2023Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  3. [The application of submental flap in the nasopharyngectomy for nasopharyngeal carcinoma].2022Lin chuang er bi yan hou tou jing wai ke za zhi = Journal of clinical otorhinolaryngology head and neck surgery免费全文
  4. [Analysis of clinical prognosis of endoscopic salvage surgery in patients with rT2 recurrent nasopharyngeal carcinoma].2022Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  5. [Prevention and management of complications in endoscopic recurrent nasopharyngeal carcinoma surgery].2022Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  6. [Internal carotid artery embolization in endoscopic salvage surgery for recurrent nasopharyngeal carcinoma: a single-center retrospective study].2022Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  7. [The application of temporalis muscle flap in the salvage nasopharyngectomy for advanced recurrent nasopharyngeal carcinoma].2022Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  8. [Surgical treatment of recurrent nasopharyngeal carcinoma: promise and challenge].2022Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
  9. [Application of pedicle nasoseptal flap in endoscopic nasopharyngectomy for recurrent nasopharyngeal carcinoma: an analysis of 39 cases].2022Zhonghua er bi yan hou tou jing wai ke za zhi = Chinese journal of otorhinolaryngology head and neck surgery
它在 ClinicalTrials.gov 上的全部试验(任何状态)14
  1. Adjuvant vs Surgery Only in Early-stage Recurrent NPC正在招募NCT06228079牵头方III期2024-06 启动
  2. Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC正在招募NCT06235203牵头方III期2024-07 启动
  3. Early Recurrent Nasopharyngeal Cancer: the Effect of Surgery vs IMRT即将招募NCT04215510牵头方III期2021-03 启动
  4. Transnasal Endoscopic Surgery Combined With Adjuvant Immunotherapy for Recurrent NPC状态不明NCT05350891牵头方II期2022-05 启动
  5. Development and Validation of a Deep Learning System for Nasopharyngeal Carcinoma Using Endoscopic Images状态不明NCT05627310牵头方2022-11 启动
  6. Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal Carcinoma状态不明NCT05011227牵头方II期2021-08 启动
  7. The Diagnosis of NPC Using the Probe-based Confocal Laser Endomicroscopy状态不明NCT03202173牵头方不分期2017-01 启动
  8. Becotatug Vedotin Combined With a PD-1 Inhibitor in the Treatment of Locally Advanced Recurrent Nasopharyngeal Carcinoma.正在招募NCT07781358牵头方(推断)II期2026-08 启动
  9. PD-1 Inhibitor Plus Anti-EGFR Therapy And Radiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy状态不明NCT06156878牵头方(推断)II期2022-08 启动
  10. Immunotherapy and Chemotherapy in Unresectable Recurrent Loco-regionally Advanced Nasopharyngeal Carcinoma状态不明NCT04921995牵头方(推断)II期2019-04 启动
  11. Prevention and Treatment of Radiation-Induced Oral Mucositis in NPC With Houyanqing Oral Liquid正在招募NCT07311772研究中心III期2025-12 启动
  12. QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.正在招募NCT06749899研究中心III期2025-05 启动
  13. Individualized Neck Cervical Irradiation Prophylaxis Trial of NPC正在招募NCT07303023研究中心III期2025-09 启动
  14. Trial Evaluating Maintenance Chemotherapy for Metastatic Nasopharyngeal Carcinoma状态不明NCT02944708研究中心III期2015-10 启动
PubMed 以外找到的论文(未计入)11
  1. 666O Exploration of the efficacy of nimotuzumab combined with induction chemotherapy in locally advanced nasopharyngeal carcinoma: A multicenter, prospective phase III study2025Annals of Oncology论文
  2. EGCG suppresses nasopharyngeal carcinoma progression by reducing PACRG methylation via inhibition of DNA methyltransferases2025Archives of Medical Science论文
  3. Tislelizumab as adjuvant therapy following endoscopic surgery for resectable recurrent nasopharyngeal carcinoma: A phase 2 randomized clinical trial.2025Journal of Clinical Oncology论文
  4. Topology-Aware Wavelet Mamba for Airway Structure Segmentation in Postoperative Recurrent Nasopharyngeal Carcinoma CT Scans2025arXiv (Cornell University)预印本
  5. Vision-language foundation model for generalizable nasal disease diagnosis using unlabeled endoscopic records2025Pattern Recognition论文
  6. WITHDRAWN: 1440TiP Phase III randomized trial of tislelizumab plus gemcitabine/capecitabine(GX) versus tislelizumab plus gemcitabine/cisplatin(GP) as first-line therapy for recurrent/metastatic nasopharyngeal carcinoma: A prospective multic2025Annals of Oncology撤稿
  7. Effect of perioperative medical therapy on prognosis in recurrent nasopharyngeal carcinoma: A comparative effectiveness research.2024Journal of Clinical Oncology会议摘要
  8. Establishment of Endoscopic Surgical Innovative System of Recurrent Nasopharyngeal Carcinoma2022DOAJ (DOAJ: Directory of Open Access Journals)论文
  9. Myocardin immunohistochemistry index is associated with clinical prognosis in nasopharyngeal carcinoma: a clinical practice-based cohort study2022Tropical Journal of Pharmaceutical Research论文
  10. Tislelizumab Rechallenge for Recurrent or Metastatic Nasopharyngeal Carcinoma (RM-NPC) Previously Treated with Another Anti-PD1 Antibody2022International Journal of Radiation Oncology*Biology*Physics论文
  11. Deep Convolutional Neural Networks for Accurate Diagnosis of Nasopharyngeal Carcinoma in pCLE Images2021International Conference on Networking Systems of AI (INSAI)会议论文

打开 PubMed 检索ClinicalTrials.gov

癌症

视网膜母细胞瘤

Retinoblastoma

2021–2025 年中国大陆作者发表的 301 篇视网膜母细胞瘤 PubMed 英文论文中,这家医院牵头了 6 篇,占 2.0%。

牵头论文
6
2021–2025 年
牵头试验
3
任何状态,ClinicalTrials.gov
牵头的开放试验
3
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 1120222023: 0020232024: 3320242025: 112025

上海有 11 家医院列在视网膜母细胞瘤下全国有 176 家医院列在视网膜母细胞瘤下

这家医院参与的开放试验 3

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    大剂量拓扑替康用于伴复发或难治性玻璃体种植的视网膜母细胞瘤High-dose Topotecan for Retinoblastoma With Recurrent or Refractory Vitreous Seed
    分期
    早期I期
    开始
    2025-04
    登记号
    NCT06972602

    年龄 1 岁 至 12 岁(登记的条件)

    牵头:复旦大学附属眼耳鼻喉科医院上海

  2. 正在招募
    靶向 NUDT21 的 siRNA 药物用于难治性视网膜母细胞瘤Targeting NUDT21 siRNA Drugs for Patients With Refractory Retinoblastoma
    分期
    早期I期
    开始
    2024-12
    登记号
    NCT06424301

    年龄 6 个月 至 未注明(登记的条件)

    牵头:复旦大学附属眼耳鼻喉科医院上海

  3. 正在招募
    鞘内化疗用于视网膜母细胞瘤中枢神经系统转移Intrathecal Chemotherapy for Central Nervous System Metastasis in Retinoblastoma
    分期
    不分期
    开始
    2021-05
    登记号
    NCT04903678

    年龄未注明(登记的条件)

    牵头:复旦大学附属眼耳鼻喉科医院上海

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。卡片标题如有中文,为 AI 生成的译文,英文原文附后。

这些数字背后的记录
论文中的科室眼科/神经眼科耳鼻喉/头颈外科
牵头的论文6
  1. Role of additional topotecan injections (plus two) in reducing recurrence rate in retinoblastoma of group D and group E patients: a retrospective study.2025BMJ open ophthalmology
  2. Assessment of Retinal Microvasculature and Choroidal Vascularity After Intra-arterial Chemotherapy for Retinoblastoma.2024American journal of ophthalmology
  3. Low expression of NR1D1 and NR2E3 is associated with advanced features of retinoblastoma.2024International ophthalmology
  4. Multimodal Imaging of a Retinocytoma.2024Ophthalmology. Retina
  5. E2F1/CKS2/PTEN signaling axis regulates malignant phenotypes in pediatric retinoblastoma.2022Cell death & disease
  6. Quantitative evaluation of retinal microvasculature and retrobulbar vessels after intravenous chemotherapy for retinoblastoma.2021BMC ophthalmology
中文论文(未计入)2
  1. [The efficacy of topotecan versus topotecan combined with melphalan in the treatment of vitreous seeds in retinoblastoma].2025[Zhonghua yan ke za zhi] Chinese journal of ophthalmology
  2. [Clinical features of patients with retinocytoma].2021[Zhonghua yan ke za zhi] Chinese journal of ophthalmology
早期论文(2016–2020 年)4
  1. Ocular toxicity of intravitreal melphalan for retinoblastoma in Chinese patients.2019BMC ophthalmology
  2. Retrobulbar ocular blood flow changes measured by colour Doppler imaging after intra-arterial chemotherapy in retinoblastoma.2017The British journal of ophthalmology
  3. [Short-term efficacy of intravitreal injection of melphalan for refractory vitreous seeding from retinoblastoma].2017[Zhonghua yan ke za zhi] Chinese journal of ophthalmology
  4. [Eyeball salvage treatment or enucleation for advanced retinoblastoma].2016[Zhonghua yan ke za zhi] Chinese journal of ophthalmology
它在 ClinicalTrials.gov 上的全部试验(任何状态)3
  1. High-dose Topotecan for Retinoblastoma With Recurrent or Refractory Vitreous Seed正在招募NCT06972602牵头方早期I期2025-04 启动
  2. Targeting NUDT21 siRNA Drugs for Patients With Refractory Retinoblastoma正在招募NCT06424301牵头方早期I期2024-12 启动
  3. Intrathecal Chemotherapy for Central Nervous System Metastasis in Retinoblastoma正在招募NCT04903678牵头方不分期2021-05 启动

打开 PubMed 检索ClinicalTrials.gov

癌症

脊索瘤

Chordoma

2021–2025 年没有牵头脊索瘤的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

上海有 14 家医院列在脊索瘤下全国有 84 家医院列在脊索瘤下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的脊索瘤开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

癌症

神经母细胞瘤

Neuroblastoma

2021–2025 年中国大陆作者发表的 1,132 篇神经母细胞瘤 PubMed 英文论文中,这家医院牵头了 5 篇,占 0.4%。

牵头论文
5
2021–2025 年
牵头试验
1
任何状态,ClinicalTrials.gov
牵头的开放试验
1
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 0020212022: 1120222023: 0020232024: 3320242025: 112025

上海有 27 家医院列在神经母细胞瘤下全国有 321 家医院列在神经母细胞瘤下

这家医院参与的开放试验 1

依据 ClinicalTrials.gov 在 2026年11月13日 的登记,包括正在招募、即将招募和邀请入组。仅在中国临床试验注册中心(ChiCTR)登记的试验不在其中。能否参加由研究团队决定。

  1. 正在招募
    诱导化疗用于嗅神经母细胞瘤的有效性和安全性(ESICON)Efficacy and Safety of Induction Chemotherapy for Olfactory Neuroblastoma (ESICON)
    分期
    II期
    开始
    2024-03
    登记号
    NCT06255210

    年龄 18 岁 至 未注明(登记的条件)

    牵头:复旦大学附属眼耳鼻喉科医院上海

在试验总页面查看

排列:先正在招募,再即将招募和邀请入组;同类按开始时间从新到旧。不是排名。卡片标题如有中文,为 AI 生成的译文,英文原文附后。

这些数字背后的记录
论文中的科室耳鼻喉/头颈外科放疗科影像/核医学科
牵头的论文5
  1. Deep learning models for differentiating three sinonasal malignancies using multi-sequence MRI.2025BMC medical imaging
  2. Survival Analysis and Prognostic Factors After Endonasal Resection of Advanced Olfactory Neuroblastomas: A Single Institution Experience.2024Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale
  3. Single-cell transcriptomic landscape deciphers olfactory neuroblastoma subtypes and intra-tumoral heterogeneity.2024Nature cancer
  4. The value of elective neck irradiation in management of esthesioneuroblastoma: a retrospective study based on propensity score matching.2024Radiation oncology (London, England)
  5. The prognostic value of S-100 protein and Ki-67 index in olfactory neuroblastoma.2022Japanese journal of clinical oncology
早期论文(2016–2020 年)5
  1. Prognostic factors and outcomes of multimodality treatment in olfactory neuroblastoma.2020Oral oncology
  2. Neck management in patients with olfactory neuroblastoma.2020Oral oncology
  3. Management of orbital invasion in esthesioneuroblastoma: 14 years' experience.2019Radiation oncology (London, England)
  4. Intravoxel incoherent motion MRI for differentiating sinonasal small round cell malignant tumours (SRCMTs) from Non-SRCMTs: comparison and correlation with dynamic contrast-enhanced MRI.2018Clinical radiology
  5. Differentiation of olfactory neuroblastomas from nasal squamous cell carcinomas using MR diffusion kurtosis imaging and dynamic contrast-enhanced MRI.2018Journal of magnetic resonance imaging : JMRI
它在 ClinicalTrials.gov 上的全部试验(任何状态)1
  1. Efficacy and Safety of Induction Chemotherapy for Olfactory Neuroblastoma (ESICON)正在招募NCT06255210牵头方(推断)II期2024-03 启动

打开 PubMed 检索ClinicalTrials.gov

其他疾病

大动脉炎

Takayasu arteritis

2021–2025 年没有牵头大动脉炎的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

上海有 8 家医院列在大动脉炎下全国有 100 家医院列在大动脉炎下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的大动脉炎开放试验。

这些数字背后的记录
早期论文(2016–2020 年)1
  1. Takayasu arteritis presenting as isolated anterior ischemic optic neuropathy.2018International ophthalmology

打开 PubMed 检索ClinicalTrials.gov

其他疾病

白塞病

Behçet disease

2021–2025 年没有牵头白塞病的 PubMed 英文论文。下方可查看与这家医院关联的研究记录。

牵头论文
0
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头

上海有 14 家医院列在白塞病下全国有 139 家医院列在白塞病下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的白塞病开放试验。

这些数字背后的记录

打开 PubMed 检索ClinicalTrials.gov

其他疾病

Leber 遗传性视神经病变

Leber hereditary optic neuropathy

2021–2025 年中国大陆作者发表的 52 篇Leber 遗传性视神经病变 PubMed 英文论文中,这家医院牵头了 1 篇,占 1.9%。

牵头论文
1
2021–2025 年
牵头试验
0
任何状态,ClinicalTrials.gov
牵头的开放试验
0
正在或即将招募
作为研究中心的开放试验
0
由其他机构牵头
每年牵头的论文数
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

上海有 3 家医院列在Leber 遗传性视神经病变下全国有 30 家医院列在Leber 遗传性视神经病变下

截至 2026年11月13日,ClinicalTrials.gov 上没有列出这家医院的Leber 遗传性视神经病变开放试验。

这些数字背后的记录
论文中的科室眼科/神经眼科

打开 PubMed 检索ClinicalTrials.gov

联系这家医院

出示给工作人员或司机的院名卡

复旦大学附属眼耳鼻喉科医院

Eye & ENT Hospital of Fudan University

上海

大医院往往有多个院区,出发前请先向医院确认院区。

中英对照的咨询信

填写方括号中的内容后,通过医院国际医疗部或官网上的联系方式发送。在这里输入的内容不会离开您的设备。

医院通常需要的资料

  • 主治医生近期的病情总结或信件
  • 病理报告
  • 影像检查(CT、MRI、PET)及报告,尽量附影像文件
  • 已接受的治疗及时间
  • 目前用药

下一步建议

与主治医生沟通可将本页分享给主治医生,一同评估该团队的研究方向是否相关。
确认团队现状论文发表通常滞后数月,医生也可能调动。请在医院官网查询相关科室。
直接联系医院请通过医院官方公布的渠道联系。医院不向我们支付任何费用;是否接诊由医院决定。

这些数字从哪里来

论文

2021–2025 年 PubMed 英文论文中,第一作者或最后作者的第一单位是这家医院的论文。 定义

试验

ClinicalTrials.gov 上列出这家医院为牵头方或研究中心的记录,截至 2026年11月8日。

编号与其他名称

ROR
Affiliated Eye Ear Nose and Throat Hospital; Eye and ENT Hospital of Fudan University; Eye Ear Nose and Throat Hospital; Fudan University Eye Ear Nose and Throat Hospital; Fudan Eye & ENT Hospital; Shanghai Eye and ENT Hospital

提出更正下载数据